Pulmonary hypertension in bronchopulmonary dysplasia

Sara K. Berkelhamer, Karen K. Mestan, Robin H Steinhorn

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Pulmonary hypertension (PH) is a common complication of neonatal respiratory diseases, including bronchopulmonary dysplasia (BPD), and recent studies have increased awareness that PH worsens the clinical course, morbidity and mortality of BPD. Recent evidence indicates that up to 18% of all extremely low-birth-weight infants will develop some degree of PH during their hospitalization, and the incidence rises to 25-40% of the infants with established BPD. Risk factors are not yet well understood, but new evidence shows that fetal growth restriction is a significant predictor of PH. Echocardiography remains the primary method for evaluation of BPD-associated PH, and the development of standardized screening timelines and techniques for identification of infants with BPD-associated PH remains an important ongoing topic of investigation. The use of pulmonary vasodilator medications, such as nitric oxide, sildenafil, and others, in the BPD population is steadily growing, but additional studies are needed regarding their long-term safety and efficacy.

Original languageEnglish (US)
Pages (from-to)124-131
Number of pages8
JournalSeminars in Perinatology
Volume37
Issue number2
DOIs
StatePublished - Apr 2013

Fingerprint

Bronchopulmonary Dysplasia
Pulmonary Hypertension
Infant, Newborn, Diseases
Extremely Low Birth Weight Infant
Fetal Development
Vasodilator Agents
Echocardiography
Nitric Oxide
Hospitalization
Morbidity
Safety
Lung
Mortality
Incidence
Population

Keywords

  • Chronic lung disease
  • Fetal growth restriction
  • Prematurity
  • Pulmonary vascular disease
  • Pulmonary vasodilators

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Berkelhamer, S. K., Mestan, K. K., & Steinhorn, R. H. (2013). Pulmonary hypertension in bronchopulmonary dysplasia. Seminars in Perinatology, 37(2), 124-131. https://doi.org/10.1053/j.semperi.2013.01.009

Pulmonary hypertension in bronchopulmonary dysplasia. / Berkelhamer, Sara K.; Mestan, Karen K.; Steinhorn, Robin H.

In: Seminars in Perinatology, Vol. 37, No. 2, 04.2013, p. 124-131.

Research output: Contribution to journalArticle

Berkelhamer, SK, Mestan, KK & Steinhorn, RH 2013, 'Pulmonary hypertension in bronchopulmonary dysplasia', Seminars in Perinatology, vol. 37, no. 2, pp. 124-131. https://doi.org/10.1053/j.semperi.2013.01.009
Berkelhamer, Sara K. ; Mestan, Karen K. ; Steinhorn, Robin H. / Pulmonary hypertension in bronchopulmonary dysplasia. In: Seminars in Perinatology. 2013 ; Vol. 37, No. 2. pp. 124-131.
@article{a45f761933a9472780c1f2f6feed5a33,
title = "Pulmonary hypertension in bronchopulmonary dysplasia",
abstract = "Pulmonary hypertension (PH) is a common complication of neonatal respiratory diseases, including bronchopulmonary dysplasia (BPD), and recent studies have increased awareness that PH worsens the clinical course, morbidity and mortality of BPD. Recent evidence indicates that up to 18{\%} of all extremely low-birth-weight infants will develop some degree of PH during their hospitalization, and the incidence rises to 25-40{\%} of the infants with established BPD. Risk factors are not yet well understood, but new evidence shows that fetal growth restriction is a significant predictor of PH. Echocardiography remains the primary method for evaluation of BPD-associated PH, and the development of standardized screening timelines and techniques for identification of infants with BPD-associated PH remains an important ongoing topic of investigation. The use of pulmonary vasodilator medications, such as nitric oxide, sildenafil, and others, in the BPD population is steadily growing, but additional studies are needed regarding their long-term safety and efficacy.",
keywords = "Chronic lung disease, Fetal growth restriction, Prematurity, Pulmonary vascular disease, Pulmonary vasodilators",
author = "Berkelhamer, {Sara K.} and Mestan, {Karen K.} and Steinhorn, {Robin H}",
year = "2013",
month = "4",
doi = "10.1053/j.semperi.2013.01.009",
language = "English (US)",
volume = "37",
pages = "124--131",
journal = "Seminars in Perinatology",
issn = "0146-0005",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Pulmonary hypertension in bronchopulmonary dysplasia

AU - Berkelhamer, Sara K.

AU - Mestan, Karen K.

AU - Steinhorn, Robin H

PY - 2013/4

Y1 - 2013/4

N2 - Pulmonary hypertension (PH) is a common complication of neonatal respiratory diseases, including bronchopulmonary dysplasia (BPD), and recent studies have increased awareness that PH worsens the clinical course, morbidity and mortality of BPD. Recent evidence indicates that up to 18% of all extremely low-birth-weight infants will develop some degree of PH during their hospitalization, and the incidence rises to 25-40% of the infants with established BPD. Risk factors are not yet well understood, but new evidence shows that fetal growth restriction is a significant predictor of PH. Echocardiography remains the primary method for evaluation of BPD-associated PH, and the development of standardized screening timelines and techniques for identification of infants with BPD-associated PH remains an important ongoing topic of investigation. The use of pulmonary vasodilator medications, such as nitric oxide, sildenafil, and others, in the BPD population is steadily growing, but additional studies are needed regarding their long-term safety and efficacy.

AB - Pulmonary hypertension (PH) is a common complication of neonatal respiratory diseases, including bronchopulmonary dysplasia (BPD), and recent studies have increased awareness that PH worsens the clinical course, morbidity and mortality of BPD. Recent evidence indicates that up to 18% of all extremely low-birth-weight infants will develop some degree of PH during their hospitalization, and the incidence rises to 25-40% of the infants with established BPD. Risk factors are not yet well understood, but new evidence shows that fetal growth restriction is a significant predictor of PH. Echocardiography remains the primary method for evaluation of BPD-associated PH, and the development of standardized screening timelines and techniques for identification of infants with BPD-associated PH remains an important ongoing topic of investigation. The use of pulmonary vasodilator medications, such as nitric oxide, sildenafil, and others, in the BPD population is steadily growing, but additional studies are needed regarding their long-term safety and efficacy.

KW - Chronic lung disease

KW - Fetal growth restriction

KW - Prematurity

KW - Pulmonary vascular disease

KW - Pulmonary vasodilators

UR - http://www.scopus.com/inward/record.url?scp=84876122586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876122586&partnerID=8YFLogxK

U2 - 10.1053/j.semperi.2013.01.009

DO - 10.1053/j.semperi.2013.01.009

M3 - Article

C2 - 23582967

AN - SCOPUS:84876122586

VL - 37

SP - 124

EP - 131

JO - Seminars in Perinatology

JF - Seminars in Perinatology

SN - 0146-0005

IS - 2

ER -